Sartorius Stedim Biotech has introduced the Ambr 250 High Throughput (HT) Bioreactor System, an innovative solution designed to accelerate the development of intensified cell cultures. This cutting-edge automated parallel bioreactor system is tailored specifically for perfusion culture, making it a vital tool for optimizing the production of therapeutic antibodies.
Enhanced Parallel Processing
Developed in collaboration with leading biopharmaceutical companies, the Ambr 250 HT system incorporates 12 to 24 single-use perfusion mini bioreactors, each with a working volume of 100 to 250 mL. This multi-parallel processing capability, combined with single-use perfusion components, allows researchers to conduct a higher number of experiments efficiently. As a result, the system significantly reduces both the time and cost associated with traditional bench-top perfusion bioreactors.
Streamlined Process Development
The Ambr 250 HT perfusion system supports a diverse range of hollow fiber perfusion applications. By employing a design-of-experiments (DoE) approach, it facilitates high cell density process development within a quality-by-design (QbD) framework. This ensures that the optimization of therapeutic antibody production is not only rapid but also yields high-quality results.
Innovative Design Features
At the core of the Ambr 250 HT system is its novel perfusion bioreactor assembly, which builds upon the successful Ambr 250 bioreactor design. Key components such as high-efficiency spargers, advanced perfusion pump chambers, and an industry-standard hollow fiber cell retention filter work together to enhance the cell culture process. The geometrical similarity of the mini bioreactor to larger BIOSTAT STR systems enables seamless scale-up of optimized processes, thus shortening development timelines.
User-Friendly Operation
One of the standout features of the Ambr 250 HT system is its ease of use. The fully assembled and irradiated perfusion bioreactors come equipped with all essential components, allowing researchers to set them up quickly. Additionally, single-use sensors continuously monitor critical parameters, including pressure at the culture fluid inlet and permeate outlet. This capability facilitates real-time monitoring of transmembrane pressure, pH, and dissolved oxygen levels.
Impact on Biopharmaceutical Development
The introduction of the Ambr 250 HT system signifies a major advancement in biopharmaceutical development. By enhancing the capacity for parallel processing and providing a user-friendly platform, this system empowers researchers to innovate more effectively. The ability to conduct multiple experiments simultaneously paves the way for faster iterations and improvements in therapeutic antibody production.
Future of Bioreactor Design
As the demand for biopharmaceuticals continues to rise, the Ambr 250 HT system addresses the need for efficient and scalable cell culture processes. Its design not only meets current industry needs but also sets the stage for future advancements. The integration of automation and single-use technologies illustrates a significant shift in bioreactor design philosophy, prioritizing efficiency and flexibility.
Key Takeaways
- The Ambr 250 HT Bioreactor System enhances cell culture development through automated parallel processing.
- It supports high cell density processes and is compatible with design-of-experiments methodologies.
-
User-friendly features, including real-time monitoring, streamline the setup and operation of experiments.
-
The system’s design facilitates rapid scale-up, aligning with industry trends toward efficiency and quality.
In conclusion, the Ambr 250 High Throughput Bioreactor System represents a significant leap forward in bioreactor design and cell culture process development. Its innovative features and user-centric design promise to transform the landscape of biopharmaceutical production. As the industry evolves, such advancements will be crucial in meeting the growing demands for therapeutic antibodies and other biopharmaceuticals.
Source: www.pharmtech.com
